Inhibrx Biosciences
INBX· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock +413.0% in FY2025
Mark P. Lappe is the CEO of Inhibrx Biosciences and was paid $2.9M in FY2025 (Dec).
Pay$100 in the stock at the end of FY24 → $513
Executives3
See all- 1Mark P. LappeChief Executive Officer and Chairman of the Board of DirectorsFY2025
- 2David J. Matly, M.B.A.PresidentFY2025
- 3Kelly D. Deck, C.P.A.Chief Financial OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allInhibrx Biosciences paid its 3 named executives $5.3M in total in FY2025 (Dec). CEO Mark P. Lappe was paid $2.9M of that.
| Name | |||
|---|---|---|---|
| Mark P. LappeChief Executive Officer and Chairman of the Board of Directors | Not disclosed | ||
| David J. Matly, M.B.A.President | Not disclosed | Not disclosed | |
| Kelly D. Deck, C.P.A.Chief Financial Officer | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Inhibrx Biosciences. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board1
See all- Kimberly ManhardDirector · 0 yr on the boardIndependentCompensation, Nominating and Corporate Governance—Paid as an executive
The board of the latest proxy (FY2024).
Activity
Filings4
See all| Proxy statement | DEF 14A | Apr 23, 2026 | FY2025 |
| Annual report | 10-K | Mar 19, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 16, 2025 | FY2024 |
| Annual report | 10-K | Mar 17, 2025 | FY2024 |
